Project Recommendation

Rebamipide Ophthalmic Suspension

Rebamipide Ophthalmic Suspension

Time: 2022-02-11  /  View: 1,198 times

Project Recommendation

Information on the reference formulationCommon nameRebamipide Ophthalmic Suspension
Trade NameMucosta
English NameRebamipide Ophthalmic Suspension
Dosage formEye Drops
Specification0.35ml:7mg
Holder大塚製薬株式会社
Country of marketingJapan
Features【Mechanism of action】.

Rebapite enhanced the expression of mucin genes in corneal epithelial cells, resulting in an increase in the amount of mucin in the cells and culture supernatant. In addition, it promoted the proliferation of corneal epithelial cells and the increase of conjunctival cells.

IndicationsXerophthalmia
Generic drug registration classificationClassified 3 of Chemicals
Project advantages
  • Market advantage: No such product is currently approved for sale in China.
  • The drug has a unique mechanism of action compared to similar drugs, which is different from all drugs already marketed in China for the treatment of dry eye and has fewer side effects.
  • The research and development of this product is underway, and Shanghai Baolong has a mature prescription process and relevant research experience.